twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates November 13, 2020 Press Release In vivo screening supports TRX-611 and TRX-612 as potential treatment candidates just weeks after program initiation. READ MORE
